|
Published by: Business Monitor International
Published: Oct. 1, 2006 - 62 Pages
Table of Contents
- Chapter 1 - Executive Summary
- Turkey Pharmaceuticals & Healthcare Industry SWOT
- Turkey Business Environment SWOT
- Turkey Economic SWOT
- Chapter 2 - Turkey: Business Environment Ranking
- Table: Business Environment Ranking: Middle East & Africa
- Business Environment Ranking
- Economics - Long-Term Risk
- Politics - Long-Term Risk
- Regulatory Barriers
- Domestic Sector Threat
- Market Growth Potential
- Market Size Ranking
- Chapter 3 - Market Summary
- Chapter 4 - Regulatory Regime
- Intellectual Property Developments
- Pricing and Reimbursement Issues
- Table: Turkish Pharmacy and Wholesale Mark-Ups
- Health Insurance
- Chapter 5 - Industry Developments
- Healthcare Sector
- Healthcare Delivery
- E-Health Initiative
- Drug Procurement - Bird Flu
- Pharmaceutical Sector
- Chapter 6 - Industry Forecast Scenario
- Key Growth Factors - Industry
- Table: healthcare expenditure trends
- Key Growth Factors - Macroeconomic
- Table: Turkey - Economic Activity
- Prescription Market Forecast
- Table: Prescription market trends
- OTC Market Forecast
- Table: OTC market trends
- Generics Market Forecast
- Table: Generics market trends
- Branded Market Forecast
- Table: Branded market trends
- Export/Import Market Forecasts
- Table: sector trade indicators
- Other Healthcare Data
- Table: Turkey Healthcare Indicators - Historical Data & Forecasts
- Key Risks to CHAPTER - BMI’s Forecast Scenario
- Chapter 7 - Company Profiles
- Indigenous Manufacturers
- Actavis (formerly Fako)
- Eczacibasi Pharmaceuticals
- Deva Holding
- Foreign Manufacturer
- Bayer
- Chapter 8 - BMI Forecast Modelling
- How We Generate Our Industry Forecasts
- Pharmaceutical Industry
- Sources
- Chapter 9 - Country Snapshot: Turkey Demographic Data
- Section 1: Population:
- Table: Demographic Indicators (2005)
- Table: Rural/Urban Breakdown
- Section 2: Education & Healthcare
- Table: Education
- Table: Healthcare: Vital Statistics
- Table: Healthcare: Expenditure
- Section 3: Labour Market And Spending Power
- Table: Employment Indicators
- Table: Consumption and Stratification
- Chapter 10 - Appendix: Regional Demographic Data
- The Long View: Data Over The Economic Cycle (2000-2007)
- Population
- Household Spending Per Capita, US$
- Private Consumption Per Capita, US$ PPP
- Market Size, GDP, US$bn
AbstractThe Turkish drug market is witnessing rapid growth as the country's recovery from the 2002 economic crisis picks up pace. According to BMI, pharmaceutical sales should reach US$11.1bn in 2010. Interest rates have been reduced in the country, a move set to boost consumer spending on pharmaceuticals. In the long term, the country's young and growing population, in addition to the possibility of closer involvement with the European Union, should help the drug market to continue to expand.
Meanwhile, recent reforms of the country's social security system are also set to have a dramatic impact on drug expenditure. This will involve the introduction of a basic universal health insurance system, which will cover 90% of the population. When combined with other key reforms, such as the availability of more cost-effective pharmaceuticals, this should go some way to providing affordable healthcare and, hence, expand the marketplace in the longer term.
BMI's adjusted Business Environment Rankings for the Middle East & Africa reveal that Turkey is in 3rd place. This is primarily due to forecasts of high market growth, coupled with the sheer size of the pharmaceutical market in the country. Turkey's poor regulatory system is an investment barrier, as is its policy of strict price controls. The country's long term political and economic outlook is improving, as the government toes the IMF line on economic policy and also looks towards EU accession.
Turkey's intellectual property regime has improved in recent years, but is still widely regarded as lax. In 2005, US trade association PhRMA recommended Turkey be placed on the Office of the US Trade Representative (USTR)'s Special 301 Watch List on market access barriers. This was primarily due to concerns over the country's inadequate data exclusivity laws, stringent price controls and the lack of an effective patent linkage system. Government procurement policies are also biased towards generic producers, with research-based drugmakers citing the fact that they have had to reduce prices by 20%, while generic manufactures have only had to cut them by 2.5%.
Key Benefits of Report
Rely On Our Independent 5-Year Forecasts As A Benchmark
to test other views - a key input for successful budgetary and strategic business planning.
Target Business Opportunities & Risks
through our reviews of latest industry trends, regulatory changes, and major deals, projects and investments
Exploit Latest Competitive Intelligence & Company SWOTS
on your competitors and peers through company rankings by sales, market share and ownership structure - includes multinational and national companies.
Get Full Details About This Report >>
|
